Figure 3

Study participants, 1 May 2022 to 31 March 2023. Participants were between 6 and 11 years of age, public school-going, and vaccinated with at least one dose of BNT162b2. We excluded: (1) individuals who received completed vaccination with other than homologous BNT162b2; (2) individuals within 14 days of receipt of their second dose.